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Objective: Hemochromatosis is an autosomal recessive disease that 
is one of the most important reasons for iron overload. Sickle cell 
disease is a hemoglobinopathy that occurs as a result of a homozygous 
mutation in the hemoglobin gene. Erythrocyte transfusion is 
frequently used in the treatment of this disease. Iron overload as a 
result of transfusion is important in the mortality and morbidity of 
sickle cell anemia patients as well as in other hemoglobinopathies. 
In this study, the effect of hemochromatosis gene (HFE) p.H63D 
and p.C282Y mutations on transfusion-related cardiac and liver 
iron overload in sickle cell disease patients who carry homozygous 
hemoglobin S mutation has been investigated. 
Materials and Methods: This is a prospective single-center cross-
sectional study in patients with homozygous hemoglobin S mutation 
between the years 2008 and 2013. The patients were divided into 
two groups. The first group (group A, n=31) was receiving chelation 
therapy and the second group (group B, n=13) was not. Direct and 
indirect iron loads were analyzed by magnetic resonance imaging and 
biochemically, respectively. HFE gene mutations were analyzed by 
polymerase chain reaction-restriction fragment length polymorphism 
method. Statistical analyses were performed by independent samples 
t-test. 
Results: p.H63D mutation was detected in 10 (32.3%) patients in 
group A and in only 1 patient (7.7%) in group B. When the 2 groups 
were compared for iron overload, iron deposition in the liver was 
significantly higher in group B (p=0.046). In addition, in group A, iron 
deposition was significantly higher in HFE mutation carriers compared 
to patients without the mutation (p=0.05). 
Conclusion: Results of this study showed that HFE gene mutations 
are important in iron deposition in the liver in patients with sickle 
cell disease. 
Keywords: Hemochromatosis, HFE gene, Iron overload, p.C282Y, 
p.H63D, Sickle cell anemia
Amaç: Hemokromatozis, demir birikiminin önemli nedenlerinden 
biri olan otozomal resesif bir hastalıktır. Orak hücreli anemi, 
hemoglobin genindeki homozigot mutasyon sonucu ortaya çıkan bir 
hemoglobinopatidir. Eritrosit transfüzyonu, bu hastalığın tedavisinde 
sıklıkla kullanılmaktadır. Transfüzyonun yarattığı demir yükü diğer 
hemoglobinopatilerde olduğu gibi orak hücreli anemi hastalarının 
mortalite ve morbiditesinde önem kazanmaktadır. Bu çalışmada 
hemokromatozis geni (HFE) p.H63D ve p.C282Y mutasyonlarının, 
homozigot hemoglobin S mutasyonu taşıyan orak hücreli anemi 
hastalarında, kalp ve karaciğerde transfüzyonla ilişkili demir 
yüklenmesine olan etkisi araştırılmıştır.
Gereç ve Yöntemler: Bu çalışma, homozigot hemoglobin S mutasyonu 
olan hastalarda 2008-2013 yıllarını kapsayan prospektif, tek merkezli 
kesitsel bir çalışmadır. Hastalar şelasyon tedavisi alan (n=31) ve 
almayan (n=13) olarak iki gruba ayrıldı. Hastalarda direk ve endirekt 
demir yükü sırasıyla manyetik rezonans görüntüleme ve biyokimyasal 
olarak analiz edildi. HFE geni mutasyon analizi polimeraz zincir 
reaksiyonu-restriksiyon fragment uzunluk polimorfizmi yöntemleri 
ile gerçekleştirildi. İstatistik analizi Independent samples t-testi 
uygulanarak gerçekleştirildi.
Bulgular: p.H63D mutasyonu grup A’da 10 hastada (%32,3), grup B’de 
ise sadece 1 (%7,7) hastada saptandı. Demir birikimi açısından gruplar 
karşılaştırıldığında karaciğerde demir birikiminin grup B’de istatistiksel 
olarak anlamlı derecede yüksek olduğu görülmüştür (p<0,05). Grup 
A’da, mutasyonu olan bireylerde olmayanlara göre karaciğerdeki 
demir birikiminin istatistiksel olarak anlamlı derecede yüksek olduğu 
görülmüştür (p=0,05).
Sonuç: Bu çalışmanın sonucu HFE genindeki mutasyonların, orak 
hücreli anemi hastalarında karaciğerde demir birikimi üzerinde etkili 
olduğunu göstermektedir.
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Introduction
Hereditary hemochromatosis (HH) is an autosomal recessive 
disease that is one of the important reasons for transfusion-
unrelated iron deposition [1]. The hemochromatosis (HFE) gene, 
encoding a transferrin receptor binding protein that regulates 
iron absorption from the intestine, is responsible for the disease 
and its point mutations result in increased iron absorption and 
accumulation [2,3]. 
The penetrance of the disease is low, as only 1% of p.C282Y 
homozygous individuals have clinical presentations. The 
disease phenotype results from primary or secondary causes. 
Primary (hereditary) hemochromatosis is usually due to gene 
mutations including the HFE gene as well as other genes 
including transferrin receptor-2 and ferroportin. Secondary 
hemochromatosis is a result of inherited or acquired anemia 
requiring frequent erythrocyte transfusions [1]. The hereditary 
causes of secondary hemochromatosis include thalassemia, 
hereditary spherocytosis, and sideroblastic anemia, and the 
acquired diseases include  anemia due to blood loss [1]. 
Sickle cell anemia is a hemoglobinopathy resulting from 
a homozygous point mutation in the hemoglobin gene 
characterized by sickling of erythrocytes [4]. Sickling results in 
vaso-occlusion, hemolysis, and chronic anemia, which results in 
increased cardiac output due to volume overload and hypoxia as 
a result of vaso-occlusion, which ends with organ dysfunction 
[5]. Erythrocyte and blood transfusions are frequently used in 
the treatment of the disease. Transfusion-related iron overload 
is important in mortality and morbidity of sickle cell anemia 
patients like in other hemoglobinopathies [3,6]. Mutation 
frequencies are known to be different between ethnic groups.
In the current study, the relationship between HFE gene p.H63D 
and p.C282Y mutations and iron deposition occurring during 
sickle cell anemia progress and their effect on cardiac and liver 
iron overload have been investigated.
Materials and Methods
Patients 
The study was performed as a prospective, single-center, cross-
sectional study on homozygous hemoglobin S mutation patients 
followed in the adult hematology department between 2008 
and 2013. A total of 45 patients aged between 20 and 42 years 
were enrolled in the study and divided into two groups according 
to administration of chelation treatment. Patients in group A 
(n=31) were receiving chelation treatment and those in group B 
(n=13) were not. There were 21 male and 10 female patients in 
group A and 4 male and 9 female patients in group B. Patients 
in group A received deferasirox (Exjade, Novartis, Switzerland) 
therapy when they had evidence of chronic transfusional iron 
overload. This evidence included the transfusion of at least 
100 mL/kg of packed red blood cells, or a serum ferritin level 
consistently greater than 1000 µg/L. Initial daily dose was 20 
mg/kg, per os. All patients required escalation of 5 to 10 mg/kg 
per daily dose to keep serum ferritin from consistently falling 
from baseline. If the serum ferritin fell below 500 µg/L, the 
therapy was interrupted. Duration of therapy was 30 months 
(range: 18-44 months).
Patients with contraindications for magnetic resonance imaging 
(MRI) were excluded from the study. Clinical and laboratory 
information of the patients was obtained from the hospital 
information management system (Nucleus v9.3.39, Monad Ltd., 
Ankara, Turkey). 
Hematological and Biochemical Analyses 
Blood cell count and aspartate aminotransferase and alanine 
aminotransferase levels were analyzed by automatized methods 
in the laboratory. Serum iron concentration (normal range: 59-
158 µg/dL), transferrin saturation (normal range: 15%-75%), 
serum ferritin (normal range: 40-340 ng/mL for males and 
14-150 ng/mL for females), and C-reactive protein levels were 
detected by enzyme-linked immunosorbent assays.
Magnetic Resonance Imaging Analyses 
All imaging analyses were performed as described previously 
with slight modifications, and a 1.5T MRI system was used for 
these analyses (Avanto, Siemens, Erlangen, Germany) [7,8,9]. 
Briefly, liver and myocardial measurements included T2* value 
screenings. Screening time was 14 s. The scan duration was 14 
s. The T2* of the heart was assessed by a cardiac gated single 
breath-hold multiecho technique. Midventricular short-axis 
images were obtained using a gradient-echo sequence (FOV, 
440 mm; TR, 120 ms; TE, 3.0-21.7 ms [8 echo times]; flip 
angle, 20; slice thickness, 10 mm; matrix, 256x104; number of 
averages, 1; bandwidth in Hz/pixel, 814). To measure the liver 
iron concentration (LIC), phased-array torso coils were used for 
signal detection. The lung was excluded on the axial plane as 
much as possible. Liver T2* values were assessed by single breath-
hold multiecho technique. Axial images through the liver were 
obtained using a gradient-echo sequence (FOV, 400; TR, 120 ms; 
TE, 4.3-20.2 ms [6 echo times]; flip angle, 20; slice thickness, 10 
mm; matrix, 256x80; number of averages, 1; bandwidth in Hz/
pixel, 814). T2* measurements were performed with Thalassemia 
Tools (Cardiovascular Imaging Solutions, London, UK). A full-
thickness region of interest was drawn in the interventricular 
septum. The signal intensity of this region for each echo time 
was measured and plotted as an exponential signal decay curve. 
The lower limit of normal for T2* in the detection of myocardial 
iron deposition has been reported as 20 ms, and this value was 
used as the cut-off in this study [7,8,9]. A T2* value of >20 
ms indicated no cardiac iron overload, and ≤20 ms indicated 
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cardiac iron overload [10]. Liver iron deposition was evaluated 
by R2* value (R2*=1000/T2*). The R2* value was converted to 
a liver biopsy equation by using the calibration curve drawn 
during the study [11]. LIC in dry tissue of >1.6 mg Fe/g was 
regarded as hepatic siderosis.
HFE Gene p.H63D and p.C282Y Mutation Analyses
DNA isolation was done from peripheral blood samples of the 
patients who were included in the study and signed the informed 
consent form. HFE gene p.H63D and p.C282Y mutations were 
analyzed by polymerase chain reaction (PCR)-restriction 
fragment length polymorphism. Primer sequences and product 
sizes for p.H63D and p.C282Y mutations are shown in Table 1. 
PCR conditions were 15 min at 95 °C for initial denaturation, 
followed by 35 cycles of 45 s at 94 °C, 30 s at 58 °C, and 30 s 
at 72 °C. The PCR was completed after a final elongation step 
of 7 min at 72 °C. PCR products were digested with BclI and 
RsaI restriction endonucleases for H63D and C282Y mutation 
analyses, respectively. The band lengths after digestion are 
shown in Table 1. A gel image of the digested products is shown 
in Figure 1. 
Statistical Analysis
The Kolmogorov-Smirnovtest was used to show the normal 
distribution of the data. Significant differences between groups 
were determined using t tests. Data were expressed as means. 
All statistical analyses and tests were performed with the SPSS 
statistical package (SPSS 17.0, Chicago, IL, USA) and p<0.05 was 
regarded as statistically significant.
Results
A total of 45 patients aged between 20 and 42 years were enrolled 
in the study. There were 20 male and 11 female patients in group 
A and 5 male and 9 female patients in group B. All patients 
were homozygous for the hemoglobin S mutation. Biochemical 
and MRI results of group A and group B patients are shown in 
Table 2. When the 2 groups were compared for iron deposition 
in the liver, iron deposition was found to be significantly lower 
in group A (p=0.05). In addition, platelet count was found to be 
significantly higher in group A (p<0.03). We did not observe a 
statistically significant difference between the 2 groups when 
other MRI and biochemical values were compared.
HFE gene H63D mutation was detected in 10 (32.3%) patients 
in group A and in 1 (7.7%) patient in group B (Table 3). In group 
A, liver iron deposition was significantly higher in patients 
with mutations compared to the patients without mutations 
(p=0.05) (Table 4). C282Y mutation was not observed in any of 
the patients included in the study (Table 3).
Discussion
Humans do not have a physiologic mechanism to excrete excess 
iron absorbed from the intestine. Iron metabolism is strictly 
controlled by intestinal absorption [12]. In the case of increased 
iron absorption, iron deposits occur in all organs. As iron 
accumulation is a problem directly influencing the prognosis 
in sickle cell disease patients, we proposed that coexisting HFE 
mutations could contribute to the deposition process in these 
cases.
HH is characterized by hepatic fibrosis, cirrhosis, diabetes, 
skin pigmentation, hypogonadism, and articular and cardiac 
disorders and, in advanced stages of the disease, iron deposition 
in other organs as a result of increased iron absorption from the 
intestines [10]. The disease occurs as a result of HFE gene H63D 
and C282Y mutations [13]. 
Figure 1. Gel image of H63D and C282Y mutations analyzed 
by polymerase chain reaction-restriction fragment length 
polymorphism. Lanes 1 and 5 are uncut polymerase chain 
reaction products, lanes 2 and 3 are samples from patients normal 
for H63D mutation, and lane 4 is a heterozygous patient sample. 
Lanes 6-8 are normal patient samples for C282Y mutation.
Table 1. Primer sequences, amplicon lengths, and restriction enzymes used in the study.
Mutation Forward Primer (5’-3’) Reverse Primer (5’-3’) Amplicon (bp) Restriction 
Endonuclease Enzyme
p.H63D ACATGGTTAAGGCCTGTTGC GCCACATCTGGCTTGAAATT 208 BclI
p.C282Y TGGCAAGGGTAACAGATCC CTCAGGCACTCCTCTCAACC 387 RsaI
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Sickle cell anemia is one of the most frequent hereditary anemias 
resulting from a homozygous point mutation in the hemoglobin 
gene [14]. Endothelial cell activation and microvascular ischemia 
may cause tissue damage in sickle cell anemia, and the spectrum 
of clinical outcomes and tissue damage severity varies among 
individuals. Because of the above findings, it was suggested that 
although sickle cell anemia is a single-gene disease, it should 
be assessed as a multifactorial disorder [15]. Blood transfusion 
and blood change, used frequently in the treatment of the 
disease, cause a decrease in erythrocyte number and sickle 
cell hemoglobin polymer formation. However, as a result of 
treatment, iron deposition and organ damage occur in patients 
[12,16]. In our study, the relationship between iron deposition 
and HFE gene H63D and C282Y mutations has been investigated. 
A total of 45 patients were enrolled in the study. 
HFE gene mutations have been investigated in another 
hemoglobinopathy, thalassemia, and the presence of a single 
mutation was not found to affect iron overload [3]. The effect 
of the presence of these mutations has been also investigated in 
sickle cell anemia and they were not found to affect the degree 
of iron overload [13,14].
C282Y mutation was observed in 90% of hemochromatosis 
patients previously [10]. We did not observe this mutation in 
our patients. On the other hand, we observed H63D mutation in 
a heterozygous state in 9 patients (29%) and in a homozygous 
state in 1 (3%) patient in group A. The mutation was observed 
in a heterozygous state in only 1 patient in group B (Table 3). 
The effect of H63D mutation on iron deposition has not yet 
been clearly identified. Iron deposition in the liver was found 
to be significantly higher in group B (p<0.05). In the literature, 
in some sickle cell patients who received chelating agents, iron 
deposition in tissues was observed, whereas in others it was not 
[1,4]. Our results show that genetic backgrounds of patients 
affect the results of the treatment and clinical benefits from 
treatment. 
The C282Y mutation has been reported to be more effective 
in iron absorption equilibrium than the H63D mutation [2,10]. 
As we did not find the C282Y mutation in our patients, we 
concluded that the H63D mutation could also be effective on 
iron absorption even in the heterozygous state. 
Table 2. Biochemical and magnetic resonance imaging results of patients in group A and group B. Liver iron deposition and 
platelet count were found to be significantly different in group A compared to group B (*p<0.05).
t-test
Mean Distributions
Group A Group B Highest Lowest p-value
Cardiac MRI (T2*, ms) 20.4 27.7 -19.78 5.03 0.238
Liver MRI (Fe, mg/g) 1.2 2.1 -1.83 -0.02 0.046*
Ferritin (ng/mL) 547.9 809.6 -734.08 210.76 0.259
Transferrin saturation (%) 46.7 27.8 -0.47 38.35 0.055
CRP (mg/L) 14.8 16.1 -15.04 12.44 0.845
ALT (U/L) 23.1 31.0 -20.99 5.10 0.209
AST (U/L) 40.6 48.9 -27.95 11.53 0.377
Leukocyte count (x103/µL) 12.5 11.0 -1.37 4.42 0.290
Platelet number (x103/µL) 430.1 329.6 10.27 190.64 0.030*
Serum albumin (g/dL) 3.9 3.7 -0.57 1.03 0.543
Creatinine (mg/dL) 0.8 0.9 -0.62 0.30 0.483
Hemoglobin (g/dL) 9.2 9.3 -1.32 1.00 0.782
MCV (fL) 89.3 89.9 -11.26 10.02 0.905
MRI: Magnetic resonance imaging, CRP: C-reactive protein, ALT: alanine aminotransferase, AST: aspartate aminotransferase, MCV: mean corpuscular volume.
Table 3. Genotype and allele frequencies of patients in the 
2 groups.
  p.H63D p.C282Y
Group A
 
Genotype
CC 21 GG 31
CG 9 GA -
GG 1 AA -
 
Allele frequency (%)
C 82.3 G 100
G 17.7 A 0
Group B
 
Genotype
CC 13 GG 14
CG 1 GA -
GG - AA -
 
Allele frequency (%)
C 96.4 G 100
G 3.6 A 0
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Although determination of ferritin level is an indirect method, it 
is one of the most valuable tools for follow-up of iron overload in 
patients with hemoglobinopathy. The source of the ferritin in the 
blood may be different. In the case of high levels of ferritin (3000 
µg/L), the possible source is blood and bone marrow; however, if 
the measurable level of ferritin is below 3000 µg/L, the possible 
source of ferritin is the reticuloendothelial system. Fluctuation of 
the measured ferritin level may be observed in the case of infection 
or inflammations. It has already been shown that the most accurate 
indicator of total body ferritin load is liver ferritin level [9]. Although 
liver biopsy was not performed for the patients to determine the 
ferritin load of the liver, and this may be considered as a weakness 
of the study, MRI is one of the other valuable tools to determine 
ferritin load in the liver and heart, and reproducibility is one of the 
strong features of this method [11]. 
Conclusion
HFE gene mutations are effective on iron deposition in the liver 
in sickle cell disease patients. In patients for whom recurrent 
erythrocyte transfusions are required, genotyping of the HFE 
gene will be helpful while management with chelating agents 
is being planned. 
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Table 4. Biochemical and magnetic resonance imaging measurement results of patients in group A. Liver iron deposition was 
found to be significantly higher (*p=0.05) in patients with HFE mutations compared to the patients without HFE mutations.
Mean t-test
Distributions Highest p-value
HFE Mutation-negative HFE Mutation-positive Lowest
Cardiac MRI (T2*, ms) 19.429 11.061 -7.43 24.17 0.283
Liver MRI (Fe, mg/g) 0.892 2 -1.44 0.00 0.050*
Ferritin (ng/mL) 444.533 599.083 -675.17 366.07 0.528
Transferrin saturation (%) 44.625 35 -56.17 75.42 0.740
CRP (mg/L) 20.652 10 -13.22 34.67 0.364
ALT (U/L) 21.350 20.857 -6.55 7.54 0.886
AST (U/L) 34.650 47.500 -39.96 14.26 0.292
Leukocyte count (x103/µL) 12.271 12.549 -4.48 3.93 0.890
Thrombocyte number (x103/µL) 427.333 434.125 -179.93 166.34 0.932
Serum albumin (g/dL) 3.999 3.823 -1.46 1.81 0.781
Creatinine (mg/dL) 0.893 0.566 -0.31 0.96 0.277
Hemoglobin (g/dL) 9.255 9 -1.31 1.45 0.917
MCV (fL) 90.300 84.025 -8.60 21.15 0.370
MRI: Magnetic resonance imaging, CRP: C-reactive protein, ALT: alanine aminotransferase, AST: aspartate aminotransferase, MCV: mean corpuscular volume, HFE: Hemochromatosis 
gene.
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